Results 221 to 230 of about 2,808,349 (298)

Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.

The Lancet HIV, 2016
K. Squires, C. Kityo, S. Hodder, M. Johnson, E. Voronin, D. Hagins, A. Avihingsanon, E. Koenig, Shuping Jiang, K. White, A. Cheng, J. Szwarcberg, H. Cao   +12 more
semanticscholar   +1 more source

Integrase inhibitor drugs during pregnancy and congenital anomalies: A case/non-case study from the global pharmacovigilance database VigiBase®. [PDF]

Pharmacol Res Perspect
Saint-Lary L, Lacroix I, Leroy V, Sommet A.   +3 more
europepmc   +1 more source

HIV-1 Genetic Diversity and Natural Polymorphisms of the Integrase Gene in Integrase Inhibitor-Naive Patients in Harare, Zimbabwe. [PDF]

AIDS Res Hum Retroviruses, 2021
Madyadi A, Dhoro M, Shamu T, Washaya T, Kouamou V, Chimukangara B, Katzenstein D, Manasa J.   +7 more
europepmc   +1 more source

Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical Trial [PDF]

, 2010
Andrew Zolopa, Daniel S Berger, Harry Lampiris, Lijie Zhong, Steven L. Chuck, Jeffrey Enejosa, Brian P. Kearney, Andrew Cheng   +7 more
openalex   +1 more source

Real-world prevalence of integrase inhibitor resistance and virological failure since adoption as guideline-preferred therapy. [PDF]

Drugs Context
Januszka J, Drwiega E, Burgos R, Smith R, Badowski M.   +4 more
europepmc   +1 more source

Antiviral Activity and Resistance Profile of the Novel HIV-1 Non-Catalytic Site Integrase Inhibitor JTP-0157602. [PDF]

J Virol, 2022
Ohata Y, Tomonaga M, Watanabe Y, Tomura K, Kimura K, Akaki T, Adachi K, Kodama EN, Matsuzaki Y, Hayashi H.   +9 more
europepmc   +1 more source

The Terminal (Catalytic) Adenosine of the HIV LTR Controls the Kinetics of Binding and Dissociation of HIV Integrase Strand Transfer Inhibitors

, 2008
David R. Langley, Himadri Samanta, Zeyu Lin, Michael Walker, Mark Krystal, Ira B. Dicker   +5 more
openalex   +1 more source

Changes to inflammatory markers during 5 years of viral suppression and during viral blips in people with HIV initiating different integrase inhibitor based regimens. [PDF]

Front Immunol
Funderburg NT, Huang SSY, Cohen C, Ailstock K, Cummings M, Lee JC, Ng B, White K, Wallin JJ, Downie B, McComsey GA.   +10 more
europepmc   +1 more source

Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials. [PDF]

J Acquir Immune Defic Syndr, 2022
D'Antoni ML, Andreatta K, Acosta R, Martin H, Chang S, Martin R, White KL.   +6 more
europepmc   +1 more source

Glycemic Control in Patients Living With HIV Initiated on Integrase Inhibitor-Based Three-Drug Antiretroviral Therapy. [PDF]

J Pharm Technol
Gerber A, Fischetti B, Popova O, Longo M.   +3 more
europepmc   +1 more source